[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Page 10682]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-4233]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated September 16, 2004, and published in the Federal 
Register on September 30, 2004, (69 FR 58544), Noramco, Inc., 1440 
Olympic Drive, Athens, Georgia 30601, made application by renewal to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-Oxide (9053).....................  I
Morphine-N-Oxide (9307)....................  I
Amphetamine (1100).........................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the Schedule I 
controlled substances for internal testing; the Schedule II controlled 
substances will be manufactured in bulk for distribution to its 
customer.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Noramco Inc. to manufacture the listed basic classes of controlled 
substances is consistent with the public interest at this time. DEA has 
investigated Noramco Inc. to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic classes of controlled substances listed.

    Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-4233 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P